Drug repositioning as a viable business strategy.
Biovista’s President A. Persidis interview to GEN’s editor in chief, John Sterling.
“Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of drug repositioning identifies novel indications for clinical candidates that have been discontinued for their primary indications for reasons other than safety.
During this week’s podcast Dr. A. Persidis talks more about the motivations that lead drug companies to view repositioning as a viable business strategy. He discusses the key elements for achieving a successful drug repositioning program and provides specific examples of companies that have successfully repositioned their therapeutic products.”
Read More…